Why choose Xen
1. Xen is agile. Quick turnaround for new products or products already in production at Xen.
2. Xen knows assay development. We develop and optimize assays everyday, from immunoassays to genetic testing.
3. Xen is cost competitive. Our infrastructure and automation allow us to offer our clients competitive pricing for the development and production of lyophilized products.
4. Last but not least, we are just a fun bunch to work with!
We offer custom formulation and lyophilization of our patent pending BioBeads(TM) technology for proteins, enzymes, PCR reagents, and other biologicals for use in the in-vitro diagnostic and other life science industries. We also offer custom formulation and lyophilization services for bulk and vial products.
Our customers are finding that converting their reagents from a liquid form to a lyophilized form results in reagents that can be conveniently stored at room temperature. In addition, there are dramatic reductions in their carbon footprint. For example, one of our customers was able to eliminate the use of dry ice and polystyrene coolers, as well as improve their freight density, resulting in a tremendous reduction of their annual total carbon footprint.
The need to modify surfaces that resist biofouling is a growing issue in many branches of biotechnology from implanted biomaterials to biomedical diagnostics. In many of these applications the adhesion of microorganisms, cells, proteins, lipids and other biomolecules often results in suboptimal or inadequate performance of a device. By using proprietary combination of polymer coatings developed by XenBio over the past several years we can offer unique and cost-effective solutions to the customer needs. Our services range from modification of nano- and microparticle surfaces to reduce or eliminate undesirable aggregation and non-specific interactions with biological fluids, biochip and membrane surface optimization to reduce background noise during optoelectronic detection, as well as anti-biofouling coatings for stents and medical implants.
XenBio’s integrated product development approach — from identification of a gene biomarker to a fully developed immunoassay — expands the capabilities of academic laboratories, biotechnology, and pharmaceutical companies involved in generating new leads for biological markers and developing new diagnostic tools. We work in partnership with our collaborators to ensure the most efficient and cost-effective way to convert their discoveries into valid, competitive diagnostic products, or useful tools for their drug discovery efforts. For most applications, we start with a gene, proceed to recombinant protein expression followed by production of recombinant antibodies, and finally progress to assay and final kit development. Within this process we offer a variety of services and capabilities to our clients. In particular we offer antibody sandwich pair profiling using well established fluorescent LOCI technology. We also develop EMIT assays for small molecule detection as well as many other assays of unmatched precision and accuracy.
Phage Display Antibody Development
Xen’s antibody technology employs proprietary phage display techniques and a highly efficient antibody expression and purification process to rapidly generate custom antibody libraries from the array of antibody RNA produced by immunized mice. The custom expression libraries contain a diverse mixture of thousands of antibodies exhibiting a defined affinity and specificity selected from a combinatorial library of heavy and light chains derived from the immunized mice. XenBio has developed methods that enable the selection of large numbers of different antibodies from the libraries. Desirable high-affinity antibodies can be readily selected and evaluated for potential applications. We are conducting analysis on both known disease markers and potential markers in order to determine their utility for diagnostic applications. If the diagnostic utility of a protein marker is confirmed, it is then assessed for commercialization potential and high value markers are further explored. This strategy is intended to form the basis for a portfolio of novel and exclusive products.